TSC Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing aims to reduce risk while seeking solid outperformance on a total return basis.
The following ratings changes were generated on Friday, April 24.
We rate Quest Diagnostics (DGX Quote) a buy. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover.
The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, compelling growth in net income, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,350.73 | 1,101.57 | 2,196.65 | 35.08 |
Oil *
74.19
|
|
UP
42.47
|
UP
5.50
|
UP
16.60
|
UP
0.21
|
10 Yr
3.51%
SPDR Gold
107.34
|
|
+0.41%
|
+0.50%
|
+0.76%
|
+0.60%
|
Data delayed 20 minutes |
Connect with TheStreet